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Abstract. Although controversy exists in the management 
of locally advanced squamous cell carcinoma of the head 
and neck (LA-SCCHN), clinicians often use induction 
chemotherapy for treatment of the most advanced cases. One 
promising regimen combines weekly cetuximab (400 mg/m2 
loading dose followed by 250 mg/m2) with carboplatin (AUC 
of 2) and paclitaxel (90 mg/m2). We retrospectively evaluated 
patients treated with this regimen prior to definitive chemo-
radiation or surgery between May 2008 and December 2011. 
The primary endpoint used for this retrospective analysis 
was feasibility. Thirty consecutive, unselected patients 
were included. Median follow-up was 13.7 months (range, 
5.0-38.7 months). All but one patient had stage IV SCCHN. 
Dose intensity was high for carboplatin (92%), paclitaxel 
(93%) and cetuximab (85%). Grade 3-4 toxicities occurred in 
<7% of the study population and were limited to rash, neutro-
penia and infusion reactions. Response rate (RR) to induction 
chemotherapy was 97% (30% complete response, 67% partial 
response). All patients completed subsequent chemoradio-
therapy or surgery. Nineteen patients (63%) demonstrated 
a complete response and 11 patients (37%) demonstrated a 
partial response. Median overall survival and progression-
free survival data are not yet mature. The RR to therapy in 
our off-protocol experience is at least comparable to that 
observed in the two phase II studies of this regimen and 
appears superior to that observed with docetaxel, cisplatin 
and fluorouracil (TPF).
Introduction
The estimated incidence of squamous cell carcinoma of the 
head and neck (SCCHN) in the USA in 2010 was ~49,260 
cases with 11,480 mortalities (1). The majority of patients 
with newly diagnosed SCCHN present with locally advanced 
disease. Multiple treatment modalities have been utilized for 
locally advanced SCCHN (LA-SCCHN), including various 
combinations of chemotherapy, radiation therapy and surgery. 
However, the most effective combination has yet to be deter-
mined (2,3). When chemoradiotherapy is employed, the most 
commonly used standard regimen is daily radiation concur-
rent with three cycles of bolus cisplatin. Only bolus cisplatin 
and weekly cetuximab are supported by level I evidence (4).
Although chemoradiation has the potential to cure 
stage IV disease, a significant number of patients will relapse, 
particularly those with higher nodal status at presentation (5). 
Induction chemotherapy prior to definitive chemoradiation 
in patients with LA-SCCHN is one approach presently used 
to improve outcomes, although its use is controversial. Two 
phase III trials published in 2007, TAX 323 and TAX 324 (6,7), 
studied induction chemotherapy with docetaxel, cisplatin and 
fluorouracil (TPF) and provided indirect evidence of the 
efficacy of induction chemotherapy. The addition of docetaxel 
to cisplatin/fluorouracil in both studies increased response 
rates (RRs) as well as overall survival (OS) compared with 
that achieved with PF alone, however, neither study featured 
definitive standard of care chemoradiotherapy in the control 
arm. While these studies resulted in the FDA approval of 
docetaxel as part of induction chemotherapy in the USA, 
they were heavily criticized for comparing two experimental 
regimens, instead of comparing either to an accepted standard 
of care (8).
The high rates of toxicity reported in TAX 323 and 
TAX 324 led many oncologists to question the feasibility 
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of TPF. In TAX 324, 21% of patients did not proceed to 
protocol-defined chemoradiotherapy and 7% of patients did 
not proceed to potentially curative therapy (7,9). Following 
the presentation of DeCIDE (10) and PARADIGM (11) trial 
data at ASCO 2012, enthusiasm for TPF diminished further. 
However, the ultimate utility of induction chemotherapy is yet 
to be resolved. Whether induction as a concept is flawed or 
whether it has been tested with the wrong regimen thus far 
remains unknown.
One of the most promising induction chemotherapy regi-
mens evaluated to date consists of weekly cetuximab (C225), 
carboplatin and paclitaxel. Carboplatin and paclitaxel were 
used together in a phase II study consisting mainly of stage IV 
patients where a clinical complete RR of 100%, 3-year 
OS of 70% and a 3-year progression-free survival (PFS) of 
90% were demonstrated following completion of definitive 
chemoradiotherapy (12). Although the regimen was less toxic 
compared with TPF, RR to induction chemotherapy was 
preserved; RR to TPF in TAX 323 and TAX 324 was 68 and 
72%, respectively. In the study by Haraf et al (12), the RR to 
weekly carboplatin/paclitaxel was 82%. Contemporaneously, 
cetuximab was demonstrated to be efficacious in head and 
neck cancer yielding improvements in survival when used 
concurrently with radiation (13,14) and palliative chemo-
therapy (15). This led to interest in grafting cetuximab onto 
the carboplatin/paclitaxel induction backbone. This was first 
studied in a phase II clinical trial published in 2010 by Kies 
et al (16) as well as in a second phase II study by Wanebo 
et al (17). The Kies study employed six weekly doses of 
cetuximab, carboplatin and paclitaxel followed by radiation 
alone, chemoradiation or surgery using an adaptive risk-based 
strategy. All 47 patients proceeded to potentially curative 
therapy, and PFS and OS rates were 87 and 91%, respectively, 
following a median follow-up of 33 months. Response to 
induction was 96%. The Wanebo ‘organ preservation’ study 
included 74 operable patients with stage III or IV disease, each 
of whom were treated with weekly cetuximab, carboplatin and 
paclitaxel, followed by serial biopsies. In total, 65% of patients 
demonstrated a pathological complete response following 
induction and 100% demonstrated a pathological complete 
response following subsequent chemoradiation. Most recently, 
cetuximab, carboplatin and paclitaxel were evaluated with a 
different schedule, where carboplatin was administered on a 
monthly bolus (18). The RR to the induction portion of this 
study was 92%. The abstract did not report any toxicity from 
induction therapy alone, however, the total toxicity was high, 
which is likely based in part on the choice of subsequent 
chemoradiotherapy regimen.
Based upon these data, the treating clinicians at the 
University of Pennyslvania (PA, USA) viewed the combina-
tion of carboplatin, paclitaxel and cetuximab as a less toxic, 
potentially more efficacious alternative to TPF. The regimen 
was therefore adopted in 2008 as the exclusive induction 
strategy for advanced neck disease in SCCHN, typically N2b 
or greater. 
Patients and methods
Patient identification. To be considered eligible for this 
retrospective review, patients had to have been diagnosed 
with LA-SCCHN between May 2008 and December 2011, 
and treated with the induction regimen of weekly cetuximab, 
carboplatin and paclitaxel prior to definitive chemoradiation or 
surgery. Appropriate patients were identified through review 
of all subjects treated during this period at the University 
of Pennsylvania with SCCHN. Patients who received this 
regimen in the setting of recurrent or metastatic SCCHN were 
excluded. None of these identified patients were excluded from 
the analysis.
Database. Once patients were identified, we reviewed elec-
tronic medical charts to extract data for baseline characteristics 
including TNM status of the tumor, the primary tumor site, 
tumor HPV-16 status (if available), date of diagnosis, gender, 
performance status, Charlson Comorbidity Index, body weight 
throughout therapy and smoking status. Additionally, doses of 
induction chemotherapy as well as definitive chemotherapy 
and radiation regimens, date of treatment and toxicity of 
therapy were obtained. Toxicity was graded retrospectively by 
CTCAE version 3. These results were entered into a password-
protected tumor database, which was maintained in Microsoft 
Access. This retrospective collection of data was approved by 
the University of Pennsylvania Institutional Review Board.
Written informed consent. Written informed consent was 
not required as data were obtained retrospectively with the 
permission of the institutional review board. Patient data were 
de-identified upon chart extraction then maintained in a pass-
word-protected database. All patients receiving chemotherapy 
and cetuximab signed standard systemic therapy consent 
forms prior to receiving treatment.
Data collection. Toxicity data were extracted retrospectively 
through chart review of EPIC, the outpatient electronic medical 
record used at the University of Pennsylvania. The data were 
gathered from review of oncology, nutrition and radiation 
oncology provider notes. All laboratory studies acquired 
subsequent to the initiation of chemotherapy and cetuximab 
were reviewed to assess for hematologic toxicity. All non-
hematological toxicity data were obtained retrospectively 
only if they were recorded formally in a complete review of 
systems or through a standardized, itemized checklist used by 
the provider. If the data available were ambiguous in gradation 
of symptoms and severity, we defaulted to the higher grade of 
toxicity.
Treatment data were extracted from the outpatient EPIC 
system and through the inpatient order-entry system, Sunrise, 
when chemotherapy was administered on an inpatient basis. 
The nature and doses of chemotherapy were documented 
from scanned order sheets and electronic medical records. 
Doses of radiation were determined in the radiation oncology 
progress notes and in the summary completion notes. Reasons 
for changes in chemotherapy doses and regimens were docu-
mented in the oncology provider notes.
Treatment. Induction chemotherapy with cetuximab, carbo-
platin and paclitaxel was most commonly administered over 
eight weeks, with an additional loading dose of 400 mg/m2 
i.v. cetuximab administered alone the week prior to starting 
the three-drug regimen. During subsequent weeks, patients 
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received cetuximab 250 mg/m2 in combination with weekly 
carboplatin AUC 2 and paclitaxel 90 mg/m2, with standard pre-
medications of dexamethasone 12 mg i.v., diphenhydramine 
50 mg i.v. and ondansetron 24 mg i.v. Treatment cycles were 
repeated weekly for up to 8 weeks and doses were withheld or 
modified at the provider's discretion depending on the types of 
toxicities experienced.
Radiotherapy was initiated ~3 weeks after induction 
chemotherapy was completed. Target volumes, duration of 
therapy and total radiation dose were determined by the 
treating radiation oncologist based on the standard of care. All 
radiation was planned for 7 weeks of the total treatment.
Concurrent therapy during radiotherapy was determined 
at the discretion of the provider. Depending on performance 
status and prior toxicities, the regimens used included either 
high-dose cisplatin (100 mg/m2) administered every 3 weeks 
for three doses, weekly cetuximab, weekly cisplatin (30 mg/m2) 
or weekly carboplatin (AUC 2) and paclitaxel (30 mg/m2). 
If toxicities were encountered during chemoradiotherapy, 
providers either reduced the dose of the chosen regimen or 
changed to a less toxic regimen including weekly cetuximab 
(250 mg/m2), weekly carboplatin (AUC 2) or weekly cisplatin 
(30 mg/m2). There were no prescribed criteria. No other agents 
were administered.
Response. Partial or complete response to the combined 
induction chemotherapy and subsequent chemoradiotherapy 
or surgery was evaluated retrospectively through physical 
exam notation in provider notes, nasopharyngolaryngoscopy 
(NPL) where available and imaging (PET, CT or MRI). Partial 
and complete RRs were defined by the Response Evaluation 
Criteria in Solid Tumors (RECIST) criteria.
Statistical analysis. Data from Microsoft Access were exported 
into Microsoft Excel where all analysis was completed. The 
primary endpoint of this retrospective analysis was feasibility, 
as measured by the number of induction cycles tolerated. 
Other pre-specified secondary endpoints included percentage 
of patients progressing to definitive chemoradiotherapy, 
toxicity, response and overall and median survival. Overall 
and median survival curves were calculated with the standard 
Kaplan-Meier method.
Results
Patients. Thirty patients were identified in this retrospective 
analysis between May 2008 and December 2011. These consti-
tuted all treatment-naïve patients receiving induction therapy 
for LA-SCCHN at the University of Pennsylvania during that 
period. Patient and tumor characteristics are summarized in 
Table I. The median age was 58.3 years (range, 37.4-83.6), 
median performance status was 0 and median Charlson 
Comorbidity index (combined condition and age-related score) 
was 4. Thirty percent were never smokers; of the smokers, 33% 
smoked ≤10 pack-years and 37% smoked >10 pack-years. Base 
of the tongue or tonsil were the primary tumor sites in 77% of 
the patients. Table II displays the tumor and nodal distribution 
matrix. No patient had metastatic disease at the start of induc-
tion chemotherapy. All but one patient had stage IVa or IVb 
SCCHN.
HPV data. HPV data were available for 13 patients. p16 
staining as a surrogate for HPV was reported as an addendum 
to pathology reports from patient specimens. Ten patients 
tested positive. The primary sites of these ten cases were all 
either base of tongue or tonsil. The primary sites of the three 
with negative p16 staining were base of tongue, hypopharynx 
and oral cavity. 
Treatment. All patients received induction chemotherapy 
with weekly paclitaxel, carboplatin and cetuximab, followed 
by combined chemoradiotherapy (n=29) or surgery (n=1). 
Treatment disposition is further delineated in Fig. 1. In addi-
tion, four patients underwent neck dissections due to possible 
residual disease on imaging.
Induction chemotherapy and toxicity. The majority of patients 
received their intended treatment (Table III). Induction 
Figure 1. Patients' treatment course. *Of these 29 patients, 2 received chemoradiation at an outside institution and are not included in this figure.
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chemotherapy was administered over a median of 48.2 days 
(range, 13.2-53.7), with some variability in the number of pre-
planned cycles. The most common planned regimen was eight 
cycles (not including the loading dose of 400 mg/m2 cetux-
imab, which all patients received the week prior to starting 
the three-drug regimen); however, the range was from 5 to 8 
pre-planned cycles. The dose intensity for all treated patients 
was high and the number of doses withheld or reduced for all 
three agents was low (Table III).
Overall, induction chemotherapy was well tolerated 
(Table IV). There were no observed grade 5 events. The only 
grade 3-4 toxicities included rash (6.7%), neutropenia without 
fever (6.7%) and infusion reactions (3.3%). The most common 
grade 1-2 toxicities included rash (77%), nausea (37%), fatigue 
(37%), anemia (17%), alopecia (27%) and electrolyte abnormali-
ties (13%). No renal toxicity, hearing loss or febrile neutropenia 
were observed. Three patients (10%) were hospitalized during 
induction chemotherapy; two for non-neutropenic infections 
and the third for neutropenia without fever. 
The majority of patients' body weights remained stable 
throughout induction chemotherapy; 3 weeks after induc-
tion, 23% of patients gained >5% of their initial body weight 
(10% gained >10%). Twenty-one patients experienced pain 
secondary to their cancer at the start of treatment and 15 of 
these patients (71%) had significant reduction or complete 
resolution of their cancer pain and/or dysphagia during their 
induction course. 
Response to induction chemotherapy. All patients were 
evaluated by imaging with CT, MRI and/or PET, physical 
examination and NPL prior to induction chemotherapy initia-
tion. All were evaluated by physical examination and NPL 
post-induction, and 18 had imaging with MRI or PET. Using 
the medical record documentation of physical examination and 
NPL, and applying the RECIST criteria whenever possible, 
9 patients (30%) had a complete clinical or radiographical 
response to induction chemotherapy, 20 patients (67%) had 
a partial response and 1 patient (3%) had stable disease. No 
patient experienced disease progression during induction 
chemotherapy.
Chemoradiotherapy. Twenty-nine patients (97%) received 
chemoradiotherapy 3-4 weeks post-induction chemotherapy. 
All had completed their full treatment at the time of analysis. 
One patient went onto surgery due to prior head and neck 
radiation for lymphoma.
Chemoradiotherapy and toxicity. Fig. 1 summarizes the 
treatment regimens of the 29 patients who completed chemo-
radiotherapy. Two patients received their chemoradiotherapy 
at an outside institution and thus their data were only partially 
analyzed. The median radiation dose administered was 
7040 cGy (range, 2600-7040 cGy). Twenty-five of the 27 
patients received 100% of their intended dose, one patient 
received 94% and one patient received only 37%. The median 
radiation course length was 6.7 weeks (range, 5.4-9.7 weeks). 
One patient (with a course length of 9.7 weeks) had a treatment 
interruption of 3 weeks due to non-compliance, although the 
patient ultimately received 100% of the intended radiation 
dose. Another patient (with a course length of 5.4 weeks) 
Table I. Patient and tumor characteristics (n=30).
Characteristic Value
Age (years) 
  Median 58.3
  Range 37.4-83.6
Gender, n (%) 
  Male 30 (100)
  Female 0 (0)
Performance status, n (%) 
  0 25 (83.3)
  1 5 (16.7)
Charlson score, n (%) 
  2 7 (23.3)
  3 7 (23.3)
  4 8 (26.7)
  5 7 (23.3)
  6 0 (0)
  7 1 (3.3)
Smoking status, n (%) 
  Never smokers 9 (30.0)
  1-5 pk/year 8 (26.7)
  6-20 pk/year 7 (23.3)
  20-40 pk/year 3 (10)
  >40 pk/year 3 (10)
Site of primary tumor, n (%) 
  Base of tongue 15 (50)
  Tonsil 8 (26.7)
  Hypopharynx 1 (3.3)
  Larynx 2 (6.7)
  Oral cavity 4 (13.3)
HPV status, n (%) 
  p16 status unknown  17 (56.7)
  p16 positive 10 (33.3)
  p16 negative  3 (10)
pk, pack; HPV, human papilloma virus.
Table II. Tumor (T) and nodal (N) distribution (n=30).
 No. of patients by T classification  Total
 ----------------------------------------------------------------------- no. of
N Tx T1 T2 T3 T4 patients
N0   1     1
N1        0
N2a   1  1   2
N2b 2  5 2 3 12
N2c   2 1 8 11
N3  1 1  2   4
Total 2 1 10 3 14 30
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experienced several multiple day treatment interruptions and 
ultimately only received 2600 cGy (37%) of the intended 
dose due to non-compliance, despite multiple attempts to 
re-establish follow-up. The remaining 27 patients completed 
their radiation on schedule without interruption.
The initial planned concurrent chemotherapy regimen was 
changed in 9 patients (30%) due to toxicities (Fig. 1). The most 
common toxicities that required alteration of the regimen were 
hematological cytopenias and hearing loss. Table IV details 
the toxicity data for combined chemoradiotherapy. The most 
common grade 3 and 4 toxicities included mucositis, anorexia, 
odynophagia, neutropenia and thrombosis (67, 63, 41, 19 and 
7%, respectively).
Weight loss was common during chemoradiotherapy 
compared with the induction phase of treatment; 59% of 
patients lost >5% of their baseline body weight and 22% lost 
>10% of their baseline body weight. 
Surgical outcomes. The one patient undergoing primary 
surgery instead of chemoradiotherapy for definitive therapy 
had tumor invading the submucosa on microscopic pathology 
(primary site; tonsil). Four other patients underwent neck 
dissections after they completed therapy due to concern 
for residual disease on imaging. Three of these patients 
had no evidence of disease on pathological examination. 
Pathological examination of one patient revealed microscopic 
foci of residual squamous cell carcinoma at a single lymph 
node level.
Overall response. Of the 30 patients evaluated, all had 
completed their full treatment at the time of analysis. Of 
those 30, 29 underwent imaging post chemoradiotherapy, 
although the timing and type of imaging was variable. 
PET/CT was the most commonly used to follow treatment 
effect over time. In total, 27/30 patients underwent their first 
PET/CT between 2.5 months to 1 year after chemoradiation 
terminated. Applying the RECIST criteria to PET/CT, MRI 
or clinical exam, 19 (63%) had complete clinical or radio-
graphical responses at 3-6 months post-treatment, and 18 
of these patients continued to demonstrate no evidence of 
disease at their time of last follow-up (range, 5.0-38.7 months). 
One of these 19 patients sustained a local recurrence 
7.5 months after completion of chemoradiation and has since 
succumbed to progression of disease. In addition, another 
one of the 19 patients succumbed to non-cancer-related 
issues. Of the 30 patients, 11 (37%) had partial responses at 
the end of full treatment with induction chemotherapy and 
concurrent chemoradiation. Eight of these 11 patients have 
since succumbed to progression of their disease. Of the 
p16-positive patients, 8/10 (80%) had a complete response. Of 
the p16-negative patients, 1/3 (33%) experienced a complete 
response.
OS and PFS. OS and PFS are still immature since median 
follow-up is only 13.7 months (range, 5.0-38.7 months). To 
date, 9 (30%) patients have experienced progressive disease 
and 9 (30%) patients have succumbed to disease. Of the 9 
patients with progressive disease, 4 patients had a local recur-
rence (primary site; oral cavity, tonsil, supraglottic larynx, 
hypopharynx), 2 had metastatic recurrence (primary site; 
Figure 2. Overall and progression-free survival curves.
Table III. Induction chemotherapy.
Parameter Carboplatin Paclitaxel Cetuximab
Number of doses administered
  Median     7     8     8
  Range 2-8 2-8 0-8
Dose intensity, (%)
  Total doses expected 229 229 229
  Total doses administered 211 (92.1) 212 (92.6) 195 (85.2)
  Total doses held 18 (7.9) 17 (7.4) 34 (14.8)
  Total doses reduced 0 (0) 21 (9.2) 2 (0.9)
Dose intensity represents the total number of doses for all patients delivered during all of induction.
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larynx, oral cavity) and 3 had local and metastatic recurrence 
(primary site; all three with tonsil). Of the 9 mortalities, 7 
were attributed to disease progression. The eighth patient 
succumbed to unclear reasons after their last imaging 
examination demonstrated continued regression of disease. 
The ninth patient succumbed to injuries sustained in a motor 
vehicle accident while in a complete response (CR). Kaplan-
Meier curves of PFS and OS are depicted in Fig. 2. 
Discussion
The TAX 323 and TAX 324 studies revealed the high toxicity 
and compromised feasibility of TPF-induction chemotherapy. 
While some patients may elect to accept short-term toxicities 
if they are associated with a higher rate of long-term cure, 
experience with this regimen has demonstrated that toxicity 
is capable of translating into long-term harm, with many 
patients either not able to proceed to definitive therapy or with 
severe compromises to planned chemoradiotherapy regimens. 
Furthermore, high toxicity of TPF has not translated into an 
increased response. As a result, the treating clinicians at the 
University of Pennsylvania switched from TPF to carboplatin/
paclitaxel/cetuximab in May 2008, when induction chemo-
therapy was chosen.
The weekly regimen was well tolerated and the low rate 
of toxicity translated into excellent feasibility for the total 
treatment plan. The majority of patients received all intended 
cycles of induction chemotherapy, with high-dose intensity. 
The majority of patients' body weights remained stable 
throughout induction, with 30% gaining in body weight. 
Grade 3 and 4 toxicity occurred in <7% of patients. Only a 
few hospitalizations occurred during induction and a high 
proportion of patients experienced relief of cancer pain and 
dysphagia. Additionally, all 30 patients were able to advance 
to definitive therapy with the majority able to receive the full, 
intended radiation dose on schedule and without treatment 
interruptions. 
The excellent feasibility observed in our studies likely 
reflects the low toxicity of the induction regimen as well as 
the positive secondary effects from clinical responses. For 
patients restaged after induction chemotherapy, all but one 
patient had at least a partial response, with 30% obtaining 
complete response prior to initiation of chemoradiation. 
Relief of dysphagia and odynophagia likely resulted in the 
high rates of observed body weight stability, which in turn 
may have enabled our patients to more readily begin and 
complete definitive local-regional therapy. Definitive therapy 
in our cohort was fairly aggressive, as 74% of patients initi-
ated definitive radiation with concurrent high-dose cisplatin. 
Of those patients, 70% completed their course with cisplatin 
(30% with other concurrent chemotherapy). As concurrent 
chemoradiation is the therapy best shown to increase cure 
rates compared with radiation alone (19), preservation of the 
intended treatment plan and the ability to receive the full dose 
of radiation likely contribute to overall outcomes. 
Although still immature, our overall PFS and OS curves 
are inferior to those reported by Kies et al (16). This likely 
reflects the higher average stage of our patient population. 
In addition, to avoid bias, we included all patients receiving 
induction therapy, regardless of baseline PFS or other demo-
graphic variables. The higher average smoking history of our 
patient population may also contribute since tobacco history 
influences prognosis independent of HPV status (20). 
Based on the extremely favorable outcomes reported 
by Kies et al for HPV+ patients, we chose to evaluate the 
treatment outcomes of our HPV+ patients. Although HPV 
data were only available for 13 of our patients (43%), the 
80% complete RR observed in those with p16 positivity, in 
contrast to the 33% complete RR observed in those with 
p16 negativity, supports the findings of improved treatment 
response in the HPV-positive subset which has been previ-
ously reported (21-23). 
In contrast to the high rates of treatment adherence 
reported in the present study, other previously published 
studies combining induction TPF with aggressive chemo-
radiation resulted in high toxicity and a considerably lower 
feasibility. For example, in the SWOG 0216 phase II study, 
cisplatin was used concurrently with definitive radiation 
following TPF induction (2). For the 74 patients in this trial, 
there was an 85% rate of grade 3-4 toxicity during induction 
chemotherapy as well as two mortalities during induction and 
a further two during subsequent chemoradiotherapy. Sixty-one 
patients (82.4%) completed induction chemotherapy and began 
concurrent chemoradiotherapy; 50 (68%) completed chemora-
diotherapy. The design of the two major TPF trials conceded 
this limitation; in TAX 323 (6), no chemotherapy was added 
to definitive radiation and in TAX 324 (7), weekly, low-dose 
carboplatin (AUC 1.5) was administered. Even so, substantial 
toxicities and treatment delays during chemoradiation were 
observed in those receiving TPF induction.
The DeCIDE and PARADIGM trials sought to address 
whether the addition of induction chemotherapy to definitive 
chemoradiotherapy is able to improve survival. However, both 
trials were flawed at inception. In each trial, patients in the 
induction arms were treated with chemoradiotherapy regimens 
that are not generally considered as standard of care. Patients 
in DeCIDE received fluorouracil/hydroxyurea/docetaxel 
with split course radiotherapy and patients in PARADIGM 
received weekly carboplatin with standard XRT or weekly 
docetaxel with accelerated boost radiotherapy. No patient on 
the investigational arms received bolus cisplatin or cetuximab, 
the chemoradiotherapy regimens supported by phase III 
trial results and recommended by NCCN guidelines (11). 
Patients in the control arms also did not receive standard 
chemoradiotherapy. By contrast, in DeCIDE, they received 
the same regimen of split-course radiotherapy concurrent 
with fluorouracil/hydroxyurea/docetaxel used in the experi-
mental arm and in PARADIGM, they received two (not the 
standard three) courses of cisplatin. Both studies terminated 
early due to poor accrual and also failed to meet their primary 
endpoints. In light of the negative results of the DeCIDE and 
PARADIGM trials, the feasibility and efficacy of the alterna-
tive weekly carboplatin/paclitaxel/cetuximab regimen outside 
of a clinical trial setting is of increased interest to the head and 
neck oncologist faced with clinical care decisions for the most 
locally advanced patients.
Despite the number of limitations associated with DeCIDE 
and PARADIGM, we nonetheless feel that the key problem 
was the choice of induction chemotherapy regimen. TPF is 
insufficiently active, too toxic and not feasible in combination 
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with standard of care chemoradiotherapy. We believe that our 
off-protocol experience with carboplatin, paclitaxel and cetux-
imab lends support to the prospective experiences of Kies and 
Wanebo, that this regimen, outside of a formal clinical trial, is 
tolerable and very efficacious. As a result of this experience, 
we are prospectively studying induction chemotherapy regi-
mens based on this platform. If our ongoing phase II study (24) 
is positive, we hope to evaluate induction chemotherapy in a 
phase III study in which both arms receive identical standard 
of care chemoradiotherapy.
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